The results showed profound improvement of IBD clinical symptoms, including reducing the truncated Mayo scores and medication scores, as well as reduced the serum levels of antigen-specific IgE, IL-4, IL-17, TNF-α, and fecal calprotectin while those treated with either SIT alone or CB alone did not induce appreciable improvement. The gene discussed is IGHE; the disease is inflammatory bowel disease.